Roberto Vidal, Biology student, Researcher, Podcast host shared a post on LinkedIn:
“Yesterday, I had the chance to present our research on a deeply misunderstood disease at the largest hematology conference in the world – the American Society of Hematology’s 67th Annual Conference (ASH 2025).
After a summer of digging through data, mapping patient trajectories, and shaping this project from scratch, today I had the chance to share our work with dozens of physicians, researchers, and trainees who stopped by the poster.
We’re studying mast cell activation syndrome (MCAS), which is a rare, debilitating, and often overlooked disorder affecting patients’ quality of life in profound ways.
Our key finding:
Imatinib improved symptoms in most MCAS patients, a 66% response rate, making this the largest analysis of its kind to date.
Early evidence, big potential impact.
I’m beyond grateful for the chance to contribute to research that could meaningfully shape future treatment options for MCAS patients. And I could NOT have done this without the incredible mentorship of Dr. C.J. Fidler, Dr. Abhay Aradhya , and Dr. Artem Oganesyan. Thank you for believing in me, challenging me, and guiding this project forward.
Feeling inspired, honored, and energized for what’s ahead.”
More posts featuring ASH on OncoDaily.
